Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio2.16
Quick Ratio2.16
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.43 million
Price / Sales1.77
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book1.53
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,140,000.00
Net Margins-149.71%
Return on Equity-182.10%
Return on Assets-105.34%
Miscellaneous
Employees18
Outstanding Shares8,750,000
Market Cap$9.02
Soligenix, Inc. Common Stock (NASDAQ:SNGX) Frequently Asked Questions
What is Soligenix, Inc. Common Stock's stock symbol?
Soligenix, Inc. Common Stock trades on the NASDAQ under the ticker symbol "SNGX."
How were Soligenix, Inc. Common Stock's earnings last quarter?
Soligenix, Inc. Common Stock (NASDAQ:SNGX) announced its quarterly earnings data on Friday, May, 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter. Soligenix, Inc. Common Stock had a negative return on equity of 182.10% and a negative net margin of 149.71%. View Soligenix, Inc. Common Stock's Earnings History.
When is Soligenix, Inc. Common Stock's next earnings date?
What price target have analysts set for SNGX?
2 brokers have issued 12 month price targets for Soligenix, Inc. Common Stock's stock. Their predictions range from $3.00 to $5.00. On average, they expect Soligenix, Inc. Common Stock's share price to reach $4.00 in the next year. This suggests a possible upside of 263.6% from the stock's current price. View Analyst Ratings for Soligenix, Inc. Common Stock.
What is the consensus analysts' recommendation for Soligenix, Inc. Common Stock?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix, Inc. Common Stock in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Soligenix, Inc. Common Stock?
Soligenix, Inc. Common Stock saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 931,279 shares, an increase of 74.6% from the June 15th total of 533,338 shares. Based on an average daily trading volume, of 290,174 shares, the short-interest ratio is currently 3.2 days. Currently, 16.1% of the shares of the stock are short sold. View Soligenix, Inc. Common Stock's Current Options Chain.
Who are some of Soligenix, Inc. Common Stock's key competitors?
Some companies that are related to Soligenix, Inc. Common Stock include Nemus Bioscience (NMUS), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP), Onconova Therapeutics (ONTX), Ceapro (CRPOF), ProPhase Labs (PRPH), NeuroVive Pharmaceutical (NEVPF), OvaScience (OVAS), Vistagen Therapeutics (VTGN), Edge Therapeutics (EDGE), SUMMIT THERAPEU/S (SMMT), AEterna Zentaris (AEZS), BENITEC BIOPHAR/S (BNTC), Lipocine (LPCN) and Regulus Therapeutics (RGLS).
Who are Soligenix, Inc. Common Stock's key executives?
Soligenix, Inc. Common Stock's management team includes the folowing people:
- Dr. Christopher J. Schaber, Pres, CEO & Chairman (Age 52)
- Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 64)
- Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 46)
- Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 66)
- Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs
Has Soligenix, Inc. Common Stock been receiving favorable news coverage?
Headlines about SNGX stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Soligenix, Inc. Common Stock earned a coverage optimism score of 0.17 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.44 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Soligenix, Inc. Common Stock?
Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soligenix, Inc. Common Stock's stock price today?
One share of SNGX stock can currently be purchased for approximately $1.10.
How big of a company is Soligenix, Inc. Common Stock?
Soligenix, Inc. Common Stock has a market capitalization of $9.02 million and generates $5.43 million in revenue each year. Soligenix, Inc. Common Stock employs 18 workers across the globe.
How can I contact Soligenix, Inc. Common Stock?
Soligenix, Inc. Common Stock's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]
MarketBeat Community Rating for Soligenix, Inc. Common Stock (NASDAQ SNGX)
MarketBeat's community ratings are surveys of what our community members think about Soligenix, Inc. Common Stock and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
